A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFN beta drugs in the treatment of multiple sclerosis

Daniel Harari, Irit Orr, Ron Rotkopf, SE Baranzini, Gideon Schreiber

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFN beta drugs in the treatment of multiple sclerosis'. Together they form a unique fingerprint.

Medicine & Life Sciences